Top

Published in:

25-04-2023 | Mood Disorders | Maternal-Fetal Medicine

Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial

Authors: Sophia Esalatmanesh, Ladan Kashani, Maryam Khooshideh, Hossein Sanjari Moghaddam, Sahar Ansari, Shahin Akhondzadeh

Published in: Archives of Gynecology and Obstetrics | Issue 4/2024

Abstract

Purpose

Evidence has demonstrated the roles of inflammatory processes in pathogenesis of depression. We aim to assess the effects of adjunctive celecoxib with cognitive behavioral therapy (CBT), an anti-inflammatory agent, in treatment of postpartum depression and on levels of Brain-derived neurotrophic factor (BDNF) and inflammatory cytokines.

Methods

This was a randomized, double-blind, placebo-controlled trial to investigate the effects of adjunctive celecoxib with CBT on postpartum depression. Fifty outpatient women with postpartum depression, participated in this study. Patients randomly received either a celecoxib capsule twice a day or a placebo capsule twice a day for 6 weeks. Patients were assessed using the Hamilton Depression Rating Scale (HDRS) and the adverse event checklist at baseline and weeks 2, 4, and 6.

Results

Patients in the celecoxib group showed a greater decline in HDRS scores from baseline to all three study time points compared to the placebo group (p = 0.12 for week 2, p = 0.001 for week 4, p < 0.001 for week 6). Rate of response to treatment was significantly higher in the celecoxib group compared to the placebo group at week 4 (60 vs 24%, p = 0.010) and week 6 (96 vs 44%, p < 0.001). Rate of remission was significantly higher in the celecoxib group compared to the placebo group at week 4 (52 vs 20%, p = 0.018) and week 6 (96 vs 36%, p < 0.001). Levels of most inflammatory markers were significantly lower in the celecoxib group compared to the placebo group at week 6. Levels of BDNF were significantly higher in the celecoxib group compared to the placebo group at week 6 (p < 0.001).

Conclusions

Findings suggest adjunctive celecoxib is an effective treatment for the improvement of postpartum depressive symptoms.

Abbasi S-H, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J Affect Disord 141(2):308–314. https://doi.org/10.1016/j.jad.2012.03.033CrossRefPubMed

Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, Rezaei F, Akhondzadeh S (2010) The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 116(2–3):101–106CrossRefPubMed

Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, Ghaleiha A, Akhondzadeh S (2015) Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord 17(6):606–614CrossRefPubMed

Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26(7):607–611. https://doi.org/10.1002/da.20589CrossRefPubMed

Alamdarsaravi M, Ghajar A, Noorbala A-A, Arbabi M, Emami A, Shahei F, Mirzania M, Jafarinia M, Afarideh M, Akhondzadeh S (2017) Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: a randomized double-blind, placebo controlled trial. Psychiatry Res 255:59–65. https://doi.org/10.1016/j.psychres.2017.05.029CrossRefPubMed

Ali NS, Mahmud S, Khan A, Ali BS (2013) Impact of postpartum anxiety and depression on child’s mental development from two peri-urban communities of Karachi, Pakistan: a quasi-experimental study. BMC Psychiatry 13(1):274. https://doi.org/10.1186/1471-244x-13-274CrossRefPubMedPubMedCentral

Casolini P, Catalani A, Zuena AR, Angelucci L (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 68(3):337–343. https://doi.org/10.1002/jnr.10192CrossRefPubMed

Dantzer R, O’connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9(1):46–56. https://doi.org/10.1038/nrn2297CrossRefPubMedPubMedCentral

de Abajo FJ, García-Rodríguez LA (2008) Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatr 65(7):795–803. https://doi.org/10.1001/archpsyc.65.7.795CrossRefPubMed

10.

de Azevedo Cardoso T, Mondin TC, Wiener CD, Marques MB, de Avila Fucolo B, Pinheiro RT, de Souza LDM, da Silva RA, Jansen K, Oses JP (2014) Neurotrophic factors, clinical features and gender differences in depression. Neurochem Res 39(8):1571–1578. https://doi.org/10.1007/s11064-014-1349-4CrossRefPubMed

11.

Dunn AJ, Swiergiel AH, de Beaurepaire R (2005) Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29(4–5):891–909. https://doi.org/10.1016/j.neubiorev.2005.03.023CrossRefPubMed

12.

Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, Crane M, Kanik KS, Chrousos GP (2001) IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 86(10):4933–4938. https://doi.org/10.1210/jcem.86.10.7905CrossRefPubMed

13.

Faridhosseini F, Sadeghi R, Farid L, Pourgholami M (2014) Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol Clin Exp 29(3):216–223. https://doi.org/10.1002/hup.2401CrossRef

14.

Gazal M, Motta LS, Wiener CD, Fernandes JC, Quevedo LÁ, Jansen K, Pinheiro KAT, Giovenardi M, Souza DO, da Silva RA (2012) Brain-derived neurotrophic factor in post-partum depressive mothers. Neurochem Res 37(3):583–587. https://doi.org/10.1007/s11064-011-0647-3CrossRefPubMed

15.

Hayley S, Poulter M, Merali Z, Anisman H (2005) The pathogenesis of clinical depression: stressor-and cytokine-induced alterations of neuroplasticity. Neuroscience 135(3):659–678. https://doi.org/10.1016/j.neuroscience.2005.03.051CrossRefPubMed

16.

Jafari S, Ashrafizadeh SG, Zeinoddini A, Rasoulinejad M, Entezari P, Seddighi S, Akhondzadeh S (2015) Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. J Clin Pharm Ther 40(4):441–446. https://doi.org/10.1111/jcpt.12287CrossRefPubMed

17.

Jafarinia M, Afarideh M, Tafakhori A, Arbabi M, Ghajar A, Noorbala AA, Saravi MA, Agah E, Akhondzadeh S (2016) Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. J Affect Disord 204:1–8CrossRefPubMed

18.

Janssen DG, Caniato RN, Verster JC, Baune BT (2010) A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol Clin Exp 25(3):201–215. https://doi.org/10.1002/hup.1103CrossRef

19.

Jeon SW, Kim Y-K (2017) Inflammation-induced depression: its pathophysiology and therapeutic implications. J Neuroimmunol 313:92–98. https://doi.org/10.1016/j.jneuroim.2017.10.016CrossRefPubMed

20.

Kashani L, Eslatmanesh S, Saedi N, Niroomand N, Ebrahimi M, Hosseinian M, Foroughifar T, Salimi S, Akhondzadeh S (2017) Comparison of saffron versus fluoxetine in treatment of mild to moderate postpartum depression: a double-blind, randomized clinical trial. Pharmacopsychiatry 50(2):64–68. https://doi.org/10.1055/s-0042-115306CrossRefPubMed

21.

Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S (2009) A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168(3):234–237CrossRefPubMed

22.

Kendall-Tackett K (2007) A new paradigm for depression in new mothers: the central role of inflammation and how breastfeeding and anti-inflammatory treatments protect maternal mental health. Int Breastfeed J 2:6. https://doi.org/10.1186/1746-4358-2-6CrossRefPubMedPubMedCentral

23.

Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiat 71(12):1381–1391. https://doi.org/10.1001/jamapsychiatry.2014.1611CrossRef

24.

Kozisek ME, Middlemas D, Bylund DB (2008) Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 117(1):30–51. https://doi.org/10.1016/j.pharmthera.2007.07.001CrossRefPubMed

25.

Krause D, Jobst A, Kirchberg F, Kieper S, Härtl K, Kästner R, Myint AM, Müller N, Schwarz MJ (2014) Prenatal immunologic predictors of postpartum depressive symptoms: a prospective study for potential diagnostic markers. Eur Arch Psychiatry Clin Neurosci 264(7):615–624. https://doi.org/10.1007/s00406-014-0494-8CrossRefPubMed

26.

Leighton S, Nerurkar L, Krishnadas R, Johnman C, Graham G, Cavanagh J (2018) Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry 23(1):48–58. https://doi.org/10.1038/mp.2017.205CrossRefPubMed

27.

Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H (1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9(11):853–858. https://doi.org/10.1006/cyto.1997.0238CrossRefPubMed

28.

Maes M, Lin A-H, Ombelet W, Stevens K, Kenis G, De Jongh R, Cox J, Bosmans E (2000) Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms. Psychoneuroendocrinology 25(2):121–137CrossRefPubMed

29.

Masoudi M, Ansari S, Kashani L, Tavolinejad H, Hossein Rashidi B, Esalatmanesh S, Ghazizadeh-Hashemi M, Noorbala AA, Akhondzadeh S (2021) Effect of sertraline on depression severity and prolactin levels in women with polycystic ovary syndrome: a placebo-controlled randomized trial. Int Clin Psychopharmacol 36(5):238–243. https://doi.org/10.1097/yic.0000000000000367CrossRefPubMed

30.

Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, Zeinoddini A, Emami S, Akhondzadeh S (2015) Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double-blind, placebo-controlled randomized trial. Ann Pharmacother. https://doi.org/10.1177/1060028015592215CrossRefPubMed

31.

Müller N, Schwarz M, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11(7):680–684. https://doi.org/10.1038/sj.mp.4001805CrossRefPubMed

32.

Oatridge A, Holdcroft A, Saeed N, Hajnal JV, Puri BK, Fusi L, Bydder GM (2002) Change in brain size during and after pregnancy: study in healthy women and women with preeclampsia. Am J Neuroradiol 23(1):19–26PubMedPubMedCentral

33.

Olsen AMS, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Olesen JB, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH (2011) Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction. Circulation 123(20):2226–2235. https://doi.org/10.1161/circulationaha.110.004671CrossRef

34.

Pariante CM (2017) Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur Neuropsychopharmacol 27(6):554–559. https://doi.org/10.1016/j.euroneuro.2017.04.001CrossRefPubMed

35.

Piccinni A, Marazziti D, Del Debbio A, Bianchi C, Roncaglia I, Mannari C, Origlia N, Catena Dell’Osso M, Massimetti G, Domenici L (2008) Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. Chronobiol Int 25(5):819–826. https://doi.org/10.1080/07420520802387773CrossRefPubMed

36.

Pinheiro RT, Pinheiro KAT, da Cunha Coelho FM, de Ávila Quevedo L, Gazal M, da Silva RA, Giovenardi M, Lucion AB, de Souza DO, Portela LV (2012) Brain-derived neurotrophic factor levels in women with postpartum affective disorder and suicidality. Neurochem Res 37(10):2229–2234. https://doi.org/10.1007/s11064-012-0851-9CrossRefPubMed

37.

Pollmächer T, Haack M, Schuld A, Reichenberg A, Yirmiya R (2002) Low levels of circulating inflammatory cytokines—do they affect human brain functions? Brain Behav Immun 16(5):525–532. https://doi.org/10.1016/s0889-1591(02)00004-1CrossRefPubMed

38.

Schmidt M, Sørensen HT, Pedersen L (2022) Cardiovascular risks of diclofenac versus other older COX-2 inhibitors (Meloxicam and Etodolac) and newer COX-2 inhibitors (Celecoxib and Etoricoxib): a series of nationwide emulated trials. Drug Saf 45(9):983–994. https://doi.org/10.1007/s40264-022-01211-1CrossRefPubMed

39.

Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiat 64(6):527–532. https://doi.org/10.1016/j.biopsych.2008.05.005CrossRefPubMed

40.

Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S-I, Iyo M (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiat 54(1):70–75. https://doi.org/10.1016/s0006-3223(03)00181-1CrossRefPubMed

41.

Shorey S, Chee CYI, Ng ED, Chan YH, San Tam WW, Chong YS (2018) Prevalence and incidence of postpartum depression among healthy mothers: a systematic review and meta-analysis. J Psychiatr Res 104:235–248. https://doi.org/10.1016/j.jpsychires.2018.08.001CrossRefPubMed

42.

Tagawa N, Hidaka Y, Takano T, Shimaoka Y, Kobayashi Y, Amino N (2004) Serum concentrations of androstenediol and androstenediol sulfate, and their relation to cytokine production during and after normal pregnancy. Steroids 69(10):675–680. https://doi.org/10.1016/j.steroids.2004.06.003CrossRefPubMed

43.

Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003) Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170(4):429–433. https://doi.org/10.1007/s00213-003-1566-zCrossRefPubMed

44.

van der Linden MW, Gaugris S, Kuipers EJ, van Herk-Sukel MPP, van den Bemt BJF, Sen SS, Herings RMC (2009) COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiol Drug Saf 18(10):880–890. https://doi.org/10.1002/pds.1782CrossRefPubMed

45.

Yermakova A (2000) Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 6(17):1755–1776. https://doi.org/10.2174/1381612003398672CrossRefPubMed

46.

Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, Ueda N, Nakamura J (2007) Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31(5):1034–1037. https://doi.org/10.1016/j.pnpbp.2007.03.001CrossRefPubMed

47.

Zou W, Feng R, Yang Y (2018) Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression. PLoS ONE 13(6):e0197267–e0197267. https://doi.org/10.1371/journal.pone.0197267CrossRefPubMedPubMedCentral

Title: Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial
Authors: Sophia Esalatmanesh
Ladan Kashani
Maryam Khooshideh
Hossein Sanjari Moghaddam
Sahar Ansari
Shahin Akhondzadeh
Publication date: 25-04-2023
Publisher: Springer Berlin Heidelberg
Keywords: Mood Disorders
Postpartum Depression
Celecoxib
Postpartum Depression
Affective Disorder
Cytokines
Published in: Archives of Gynecology and Obstetrics / Issue 4/2024
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-023-07042-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2024

Medical students’ knowledge on cancer predisposition syndromes and attitude toward eHealth

Sonographic examination at the beginning of the second stage of labor predicts birth outcome in vaginally intended breech deliveries: a blinded prospective study

The role of the PLGF in the management of pregnancies complicated with fetal microsomia

Will I soon be out of my job? Quality and guideline conformity of ChatGPT therapy suggestions to patient inquiries with gynecologic symptoms in a palliative setting

Deprived areas and adverse perinatal outcome: a systematic review

Hemostatic agents can be considered as an at least non-inferior approach for preservation of ovarian reserve after cystectomy for endometriomas